Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Ocular Therapeutix (NASDAQ: OCUL) plans to discuss third-quarter 2026 financial results during a conference call and webcast on November 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) plans to discuss third-quarter 2026 financial results during a conference call and webcast on November 9, 2026. The call is scheduled for 8:00 AM ET and will cover recent business progress and the quarter ended September 30, 2026. The webcast will be available through the company's Investor Relations page, with a replay archived for at least 30 days.
Details
Market Reaction – OCUL
On Nov 2, the day this news came out, the latest delayed price for OCUL is 4.01% above the previous close. Our momentum scanner has recorded 18 alerts for this stock so far that day. The latest delayed price is $7.00.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
Conference Call and Webcast Information:
Date: Monday, November 9, 2026 at 8:00 AM ET
Participant Dial-In (U.S.): 1-833-419-0865
Participant Dial-In (International): 1-785-838-9333
Conference ID: OCULAR (required for entry)
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
